Peer Review History

Original SubmissionDecember 27, 2023
Decision Letter - Meryem Merve Ören Çelik, Editor

PONE-D-23-43186Feasibility and preliminary effects of a Mindfulness-Based Physical Exercise (MBPE) program for community-dwelling older people with sarcopenia: A protocol for a parallel, two-armed pilot randomised controlled trialPLOS ONE

Dear Dr. Kor, 

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 21 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Meryem Merve Ören Çelik

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Major Revision Required

This seems a very good protocol for a worthwhile, well designed feasibility trial. However, there are some important points that need to be re-examined.

Page Lines

10 181 This statement needs rephrasing from: “… 25 per group will produce at least a small standardised effect size in a main study [46].” to something like “… 25 per group is likely to provide sufficient information for planning the proposed subsequent main randomised trial with an anticipated standardised effect size of about 0.2 [46].”

18 Primary outcomes and measures: This section needs to stipulate somewhere that a primary outcome is also the estimation of the SD for the main endpoint measure. Feasibility relates to statistical aspects of the future trial as well as practicability. See comments below regarding page 24.

23 Probably best not to conduct statistical significance tests with p-values reported, but merely report (say) the mean difference between the two randomised groups with corresponding 95% confidence intervals.

24 Reference [46] states: “When the outcome is a continuous variable, the sample size calculation requires an accurate estimate of the standard deviation of the outcome measure. A pilot trial can be used to get an estimate of the standard deviation, which could then be used to anticipate what may be observed in the main trial. However, an important consideration is that pilot trials often estimate the standard deviation (SD) parameter imprecisely.”

Thus, the main statistical issue in this feasibility study is to provide information to help ascertain a meaningful standardised effect size. This requires an estimate of the SD for the intended main outcome variable for planning the size of the subsequent randomised Phase III controlled trial. Consequently, the Statistical Analysis section should state this explicitly and thus the eventual results section requires the SD to be reported.

This in turn implies that the principal endpoint for the subsequent trial needs to be identified and clearly stipulated in this Protocol.

Some minor points are listed below:

Page Lines

9 169 ‘CONSORT’ is misspelt

11 203 “Prifysgol” is the Welsh language word for “University” so need not be included here.

24 13 Reporting minimum and maximum values rather than quartiles is likely to be more informative.

24 18-19 I cannot imagine ‘generalised estimating equations; will really be necessary.

Reviewer #2: This protocol is an intervention that addresses a very important problem that concerns public health, gerontology and geriatrics due to its magnitude and significance in the healthy aging process. Sarcopenia is a predictor of dependency, loss of autonomy, increased mortality and higher health care costs. Having scientifically verifiable intervention strategies provides an incentive for their application, even more so by including two factors as important as motivation and adherence that are recognized as problems in maintaining a longer-term program. A randomized controlled pilot trial is a good initial design to continue searching for more viable actions and their effects in the prevention of Sarcopenia.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Elva Dolores Arias Merino.

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear Editor and Reviewers,

Thank you for your time to review our revised manuscript and your valuable comments and suggestions on it. We have made all of the revisions on the paper with careful considerations to your comments and they are described as below. The changes in the manuscript are also highlighted in yellow:

R1(1): 10 181 This statement needs rephrasing from: “…25 per group will produce at least a small standardised effect size in a main study [46].” to something like “…25 per group is likely to provide sufficient information for planning the proposed subsequent main randomised trial with an anticipated standardised effect size of about 0.2 [46].”

Response: We have adopted the suggestions and rephrased the sentence on Page 10, Line 182-184.

R1(2): 18 Primary outcomes and measures: This section needs to stipulate somewhere that a primary outcome is also the estimation of the SD for the main endpoint measure. Feasibility relates to statistical aspects of the future trial as well as practicability. See comments below regarding page 24.

Response: We have supplemented the primary outcome on Page 21, Line 287-288. In this pilot study, the primary outcome is handgrip strength. The standardised mean difference (Conde’s d) with corresponding 95% confidence intervals will be reported to describe the mean differences between the intervention group and the control group (Page 24, Line 367-370).

R1(3): 23 Probably best not to conduct statistical significance tests with p-values reported, but merely report (say) the mean difference between the two randomised groups with corresponding 95% confidence intervals.

Response: We adopted the suggestions and revised the method section on Page 24, Line 367-370:

The standardised mean difference with corresponding 95% confidence intervals will be presented to describe the mean differences of both primary and secondary outcomes between the intervention group and the control group [71]. All data analyses will be conducted with two-tailed tests with a significance level of p < 0.05.

R1(4): 24 Reference [46] states: “When the outcome is a continuous variable, the sample size calculation requires an accurate estimate of the standard deviation of the outcome measure. A pilot trial can be used to get an estimate of the standard deviation, which could then be used to anticipate what may be observed in the main trial. However, an important consideration is that pilot trials often estimate the standard deviation (SD) parameter imprecisely.”

Thus, the main statistical issue in this feasibility study is to provide information to help ascertain a meaningful standardised effect size. This requires an estimate of the SD for the intended main outcome variable for planning the size of the subsequent randomised Phase III controlled trial. Consequently, the Statistical Analysis section should state this explicitly and thus the eventual results section requires the SD to be reported. This in turn implies that the principal endpoint for the subsequent trial needs to be identified and clearly stipulated in this Protocol.

Response: We adopted the suggestions and revised the method section on, Page24, Line 358-361, reporting SD and Page 24, Line 367-370, stating the mean difference (see the above response #R1(3)).

Some minor points are listed below:

Page Lines

R1(5): 9 169 CONSORT is misspelt.

Response: We have revised. Thank you!

R1(6): 11 203 “Prifysgol” is the Welsh language word for “University” so need not be included here.

Response: We have deleted it. Thank you!

R1(7): 24 13 Reporting minimum and maximum values rather than quartiles is likely to be more informative.

Response: We have adopted the suggestions and added the variables of minimum and maximum values on Page 24, Line 360-361.

R1(8): 24 18-19 I cannot imagine “generalised estimating equations” will really be necessary.

Response: After consulting two statisticians, we adopted the GEE analysis because this method accounts for intra-correlated pre-test and post-test measures and accommodates missing data. Besides GEE provide robust results for non-normally distributed continuous data.

Reviewer #2: This protocol is an intervention that addresses a very important problem that concerns public health, gerontology and geriatrics due to its magnitude and significance in the healthy aging process. Sarcopenia is a predictor of dependency, loss of autonomy, increased mortality and higher health care costs. Having scientifically verifiable intervention strategies provides an incentive for their application, even more so by including two factors as important as motivation and adherence that are recognized as problems in maintaining a longer-term program. A randomized controlled pilot trial is a good initial design to continue searching for more viable actions and their effects in the prevention of Sarcopenia.

Response: Thank you for your comments!

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Meryem Merve Ören Çelik, Editor

Feasibility and preliminary effects of a Mindfulness-Based Physical Exercise (MBPE) program for community-dwelling older people with sarcopenia: A protocol for a parallel, two-armed pilot randomised controlled trial

PONE-D-23-43186R1

Dear Dr. Kor,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Meryem Merve Ören Çelik

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Accept

This seems a very good protocol for a worthwhile and well-designed study. The authors have now included the estimation of the standardised effect size for planning an eventually larger Phase III trial as an objective of this study. However, I remain concerned that the statistical analysis plan over complicates the eventual analysis that will be needed. More focus on confidence intervals rather than p-values from statistical tests of significance is likely to be required.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Formally Accepted
Acceptance Letter - Meryem Merve Ören Çelik, Editor

PONE-D-23-43186R1

PLOS ONE

Dear Dr. Kor,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Meryem Merve Ören Çelik

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .